Melanotan II vs Trazodone
Well Studied vs FDA Approved
monitor Mechanism-based · 51% Both Melanotan II and Trazodone can raise blood pressure. Monitor BP regularly and consider adding cardiovascular support (cardarine, telmisartan, or similar).
Molecular Data
Melanotan II Trazodone
Weight — 371.86 Da
Half-life ~2 hours ~5-9 hours
Type Synthetic alpha-MSH analog Triazolopyridine derivative (C19H22ClN5O)
Key Benefits
Melanotan II
01 Rapid tanning without UV exposure
02 Enhanced sexual function and libido
03 Appetite suppression
04 Improved mood via melanocortin activation
05 Photoprotection through increased melanin
Trazodone
01 Effective sleep aid that improves sleep onset and sleep maintenance without the dependence risk of benzodiazepines
02 Enhances slow-wave (deep) sleep, which is critical for physical recovery and growth hormone release
03 Non-habit-forming with no significant tolerance development, even with long-term use
04 Widely used and well-tolerated solution for trenbolone-induced and steroid-related insomnia
05 Does not suppress REM sleep the way many other sleep medications do
06 Inexpensive, widely available as a generic, and has decades of safety data
Dosing Protocols
Melanotan II
Loading: Start 0.25mg daily, increase to 0.5-1mg; Maintenance: 0.5-1mg 2-3x weekly / Loading phase: Daily for first week, then tanning maintenance 2-3x weekly or as needed for sexual enhancement
Initial loading phase 0.25mg 1x daily
Tanning maintenance 0.5-1mg 2-3x weekly
Sexual enhancement 0.5-1mg As needed
Minimal side effects 0.1-0.25mg Every other day
Photoprotection 0.5mg 2x weekly
Trazodone
25-100 mg at bedtime (sleep) / Once daily at bedtime
Side Effects
Melanotan II
Nausea (pre-treatment with antiemetics recommended)
Facial flushing
Temporary blood pressure elevation
Fatigue
Spontaneous erections
Trazodone
Morning drowsiness or grogginess (dose-dependent, more common above 50 mg)
Dry mouth
Dizziness or lightheadedness, particularly upon standing (orthostatic hypotension)
Headache
Nausea (reduced by taking with food)
Blurred vision
Contraindications
History of melanoma or dysplastic nevi
Pregnancy or breastfeeding
Cardiovascular conditions
Uncontrolled hypertension
Known hypersensitivity to trazodone
Concurrent use of MAOIs or use within 14 days of MAOI discontinuation
History of priapism or conditions predisposing to priapism (e.g., sickle cell disease, multiple myeloma, leukemia)
Severe hepatic impairment (dose adjustment required in moderate impairment)
Recent myocardial infarction or unstable cardiac conditions
Pregnancy, particularly first trimester (Category C; limited human data)
Research Evidence
Melanotan II Trazodone
Status Well Studied FDA Approved
References 4 studies 4 studies
Latest 2024 —
FDA Approved No Yes
More comparisons: BPC-157
This comparison is for educational and research purposes only. Consult a healthcare professional before use.